Table 2.
Baseline Characteristics and Descriptive Statistics by Treatment Group
| Variable Name | PE (N=17) |
CBTi.p. (N=18) |
|---|---|---|
| Demographic Characteristics [N(%)] | ||
| Age [years; M(SD)] | 59.9(10.3) | 58.9(12.2) |
| Education (years) | 14.7(2.4) | 13.4(2.4) |
| Marital Status (married) | 10(58.8) | 13(72.2) |
| Race (Caucasian) | 16(94.1) | 15(83.3) |
| Ethnicity (Non-Hispanic) | 15(88.2) | 18(100.0) |
| Physiological Characteristics [N(%)] | ||
| Body Mass Index (kg/m2; M(SD)] | 32.8(8.5) | 33.4(7.2) |
| Chemotherapy (yes) | 7(41.2) | 7(38.9) |
| Radiotherapy (yes) | 5(29.4) | 2(11.1) |
| Invasive Surgery (yes) | 10(58.8) | 7(38.9) |
| Surgical Complications (yes) | 4(23.5) | 2(11.1) |
| Length of Hospital Stay [days; M(SD)] | 3.7(2.7) | 2.9(2.4) |
| Cancer Stage | ||
| Stage I | 9(52.9) | 11(61.1) |
| Stage II | 2(11.8) | 1(5.6) |
| Stage III | 4(23.5) | 5(27.8) |
| Stage IV | 1(5.9) | 0 |
| Unknown Stage | 1(5.9) | 1(5.6) |
| Tumor Site | ||
| Endometrial | 14(82.4) | 12(66.7) |
| Ovarian | 2(11.8) | 2(11.1) |
| Fallopian Tube | 2(5.9) | 1(5.6) |
| Cervical | 0 | 1(5.6) |
| Vulvar | 0 | 2(11.1) |
| Descriptive Statistics | ||
| Completed Intervention Sessions | 4.6(2.3) | 5.2(1.8) |
| Sleep Medication Use (yes) | ||
| Rx Sedatives | ||
| T1 | 1(5.6) | 3(17.6) |
| T2 | 1(7.7) | 1(5.9) |
| T3 | 1(7.7) | 1(5.9) |
| OTC Sleep Aids | ||
| T1 | 2(11.1) | 1(5.9) |
| T2 | 1(7.7) | 0(0) |
| T3 | 1(7.7) | 0(0) |
| Rx Antidepressants | ||
| T1 | 0(0) | 1(5.9) |
| T2 | 1(7.7) | 2(14.3) |
| T3 | 1(7.7) | 3(25.0) |
| Pain Medication Use (yes) | ||
| Opioids | ||
| T1 | 7(38.9) | 8(47.1) |
| T2 | 4(30.8) | 4(28.6) |
| T3 | 4(30.8) | 3(25.0) |
| Non-Opioid Analgesics | ||
| T1 | 14(77.8) | 10(58.8) |
| T2 | 7(53.8) | 10(71.4) |
| T3 | 7(53.8) | 8(66.7) |
| Neuroleptics | ||
| T1 | 0(0) | 3(17.6) |
| T2 | 2(15.4) | 5(35.7) |
| T3 | 2(15.4) | 4(33.3) |
| AHI (per hour) | ||
| Mild Apnea (AHI 5–15; yes) | ||
| T1 | 6(35.3) | 5(29.4) |
| T2 | 6(50.0) | 3(25.0) |
| T3 | 1(11.1) | 2(16.7) |
| Moderate Apnea (AHI 16–30; yes) | ||
| T1 | 0(0) | 0(0) |
| T2 | 1(8.3) | 1(8.3) |
| T3 | 0(0) | 0(0) |
| Sleep Diary Variables [M(SD)] | ||
| Total Wake Time (minutes) | ||
| T1 | 126.9(67.9) | 88.1(45.3) |
| T2* | 93.9(44.7) | 53.7(35.3) |
| T3* | 102.4(65.9) | 44.6(30.1) |
| Sleep Onset Latency (minutes) | ||
| T1 | 49.8(25.9) | 37.4(27.3) |
| T2 | 33.0(20.3) | 23.1(24.3) |
| T3* | 36.7(25.3) | 18.3(13.1) |
| Wake After Sleep Onset (minutes) | ||
| T1 | 45.4(37.0) | 42.0(26.2) |
| T2 | 38.4(25.3) | 21.0(18.0) |
| T3 | 32.0(26.3) | 17.6(17.3) |
| Sleep Efficiency (%) | ||
| T1 | 76.0(11.4) | 81.7(9.2) |
| T2 | 81.8(7.4) | 88.0(9.1) |
| T3* | 80.0(11.6) | 90.0(6.1) |
| Sleep Quality (total score) | ||
| T1 | 2.1(0.5) | 2.0(0.5) |
| T2 | 2.2(0.6) | 2.3(0.6) |
| T3 | 2.2(0.6) | 2.3(0.5) |
| Actigraphy Variables [M(SD)] | ||
| Total Wake Time (minutes) | ||
| T1 | 107.2(45.2) | 97.9(41.3) |
| T2 | 95.4(32.9) | 82.7(24.0) |
| T3 | 88.8(35.0) | 80.3(30.7) |
| Sleep Onset Latency (minutes) | ||
| T1 | 33.6(22.3) | 29.3(22.5) |
| T2 | 29.3(17.3) | 22.4(14.2) |
| T3 | 26.7(14.9) | 24.5(15.0) |
| Wake After Sleep Onset (minutes) | ||
| T1 | 53.4(18.4) | 50.5(16.2) |
| T2 | 46.9(19.3) | 44.4(14.6) |
| T3 | 44.4(22.3) | 41.9(19.9) |
| Sleep Efficiency (%) | ||
| T1 | 79.4(7.3) | 80.8(5.4) |
| T2 | 81.8(4.6) | 82.1(5.1) |
| T3 | 82.6(5.0) | 82.4(5.6) |
| PSG Variables [M(SD)] | ||
| Total Wake Time (minutes) | ||
| T1 | 133.9(68.0) | 119.0(67.9) |
| T2 | 82.4(63.8) | 120.5(45.0) |
| T3 | 83.0(67.2) | 83.0(33.7) |
| Sleep Onset Latency (minutes) | ||
| T1 | 36.2(37.5) | 24.7(38.5) |
| T2 | 20.9(21.4) | 48.9(50.7) |
| T3 | 21.6(36.1) | 5.6(40.2) |
| Wake After Sleep Onset (minutes) | ||
| T1 | 94.8(54.1) | 91.1(51.3) |
| T2 | 82.5(65.9) | 70.6(37.5) |
| T3 | 71.6(68.2) | 49.6(61.5) |
| Sleep Efficiency (%) | ||
| T1 | 71.0(16.5) | 75.5(15.3) |
| T2 | 79.5(13.2) | 75.8(7.8) |
| T3 | 81.1(14.7) | 63.0(57.4) |
Note. Rx = Prescription; OTC = Over-the-counter; AHI = Apnea-Hypoapnea Index; REM = rapid eye movement sleep; PSG = Polysomnography.
*
Independent samples t-test (2-tailed) indicative of a significant (p<0.05) difference in group means.